Coherus Oncology Inc. reported its financial results for the second quarter of 2025, noting a significant increase in LOQTORZI net revenue, which rose to $10.0 million-a 36% increase over the first quarter of 2025. The company recorded a non-GAAP net loss from continuing operations of $39.0 million for the second quarter, an increase from the $34.7 million loss reported for the same period in 2024. For the first half of 2025, the non-GAAP net loss was $79.9 million, an improvement compared to the $88.3 million loss in the first half of 2024. Selling, general, and administrative expenses decreased to $26.0 million from $27.5 million in the same period of the previous year, attributed mainly to lower headcount and decreased operating costs following recent divestitures. The company ended the second quarter with $238 million in cash, cash equivalents, and marketable securities, asserting a cash runway through 2026. Coherus remains focused on maximizing LOQTORZI's potential in treating nasopharyngeal carcinoma and anticipates data readouts for CHS-114 and casdozokitug in the first half of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.